Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4268989 (MORF-057) PK, Safety, Food Effect and DDI Study in Healthy Participants
NCT06964776Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY4268989 in inflammatory bowel disease (IBD) (8 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration, Area Under the Concentration Curve and 1 more. Started May 2025; status: completed.
02
Drugs
LY4268989
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06964776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964776.